A real world systematic review and meta-analysis found tildrakizumab improved plaque psoriasis severity and quality of life ...

Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...

Psoriasis is a chronic, recurrent, and incurable autoimmune disease in which the body mistakenly attacks its own tissue, ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib ...

For a plaque psoriasis drug to succeed in a clinical trial, it doesn’t need to clear all of the redness and other signs of the inflammatory skin disease. But complete skin clearance is a benchmark ...

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

For people with psoriasis — a chronic skin disease in which skin cells build up, typically causing discolored, itchy or scaly patches — living with the condition itself is difficult enough. But on top ...

PsA and PPP are associated with high rates of depression, anxiety, and sleep disturbances, impacting disease severity and treatment adherence. A systematic review of 17 studies found depression ...

Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis. We conducted a phase 3, double-blind, randomized, ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...